Diversity · 10,000 compounds

MS-10000 Diversity Library

A TimTec 10,000-compound diversity collection of high-purity, drug-like screening compounds from TimTec stock.

A clear plastic 96-well microplate and a white rack holding several open amber glass vials on a white laboratory surface, with blurred laboratory glassware and white chemical structural diagrams against a teal background

MS-10000 is TimTec’s 10,000-compound diversity library. Compounds are selected from TimTec stock for general screening: high purity, structural diversity, and drug-like properties. The set is the result of multi-stage filtering of a large candidate pool on diversity and structural relevance.

Additional filters considered physical-chemical properties including MW, cLogP, H-acceptors, H-donors, and rotatable bonds. The molecular-weight range is about 120 to 500. The collection is largely drug-like according to Lipinski’s Rule of 5 and also includes lead-like material, leaving room for molecular optimization. Overly represented chemotypes and structures poorly suited for medicinal chemistry follow-up were removed during refinement.

Format and purity

MS-10000 is offered in DMSO plating formats. In addition to 1 mg/mL, a 10 mM concentration option is described on the legacy TimTec pages. Average purity is greater than 95%, with nothing below 90%. Re-supply from stock or re-synthesis is available for follow-up. Structural data and pricing are provided on request.

This collection was formerly marketed as MyriaScreen with Sigma-Aldrich; that partnership is discontinued. The current offering is TimTec’s MS-10000.

Published screens

These papers used the set under the former MyriaScreen name. That partnership is discontinued; the current TimTec offering is MS-10000. Literature reports, not TimTec efficacy claims:

  • Delgado-Soler, L.; Toral, R.; Tomás, M. S.; Rubio-Martinez, J. RED: A set of molecular descriptors based on Rényi entropy. J. Chem. Inf. Model. 2009, 49(11), 2457–2468. doi:10.1021/ci900275w. Cheminformatics / virtual-screen use of the historical collection descriptors.
  • Barrow, E. W.; Clinkenbeard, P. A.; et al. High-throughput screening of a diversity collection using biodefense category A and B priority pathogens. J. Biomol. Screen. 2012, 17(7), 946–956. doi:10.1177/1087057112448216. 10,000-compound MyriaScreen Diversity Collection against NIAID category A/B pathogens.
  • Bustad, H. J.; Toska, K.; Schmitt, C.; et al. A pharmacological chaperone therapy for acute intermittent porphyria. Mol. Ther. 2020. doi:10.1016/j.ymthe.2019.11.010. Methods name the MyriaScreen Diversity Collection (10,000 drug-like compounds).
  • Vittorio, S.; Adornato, I.; Gitto, R.; Peña-Díaz, S.; Ventura, S.; De Luca, L. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease. J. Enzyme Inhib. Med. Chem. 2020. doi:10.1080/14756366.2020.1816999. Virtual screen of MyriaScreen Diversity Library II (10,000 compounds).

Ask for the current SDF and plate map before designing a campaign; membership can change as lots are retired or replaced.

Request SDF / quote ActiProbe-10K